FINAL HOURS: Lock in your InvestingPro subscription for 50% off before sale ends
TORONTO - Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company, today addressed recent inaccuracies regarding its corporate identity and relationship with Unbuzzd Wellness Inc. The company clarified that its name remains unchanged despite some trading platforms incorrectly listing it as Unbuzzd Wellness Inc., a separate entity focused on alcohol metabolism products. The clarification comes as QNTM’s stock shows strong momentum, with a 31% gain in the past week and a remarkable 240% surge over six months, according to InvestingPro data.
The announcement follows confusion stemming from a May 29, 2025 press release, which led to erroneous reports on social media about a reverse takeover (RTO) between Quantum BioPharma and Unbuzzd Wellness Inc. Quantum BioPharma confirmed that no such RTO is currently in progress. (InvestingPro analysis suggests the stock is currently trading above its Fair Value, with 8 additional exclusive insights available to subscribers.)
Quantum BioPharma also disclosed its financial involvement with Unbuzzd Wellness Inc. As the largest shareholder and creditor, Quantum BioPharma is entitled to a 7% royalty on Unbuzzd’s revenues until a cumulative total of $250 million is paid, after which the royalty rate will decrease to 3%. Additionally, Unbuzzd Wellness Inc. has granted Quantum BioPharma 200 million post-split common shares and an anti-dilution warrant that could increase Quantum’s holding to 25% upon a public offering. With a current market capitalization of $45.46 million and a moderate debt-to-equity ratio of 0.22, InvestingPro data shows the company maintains a fair financial health score of 2.12.
Unbuzzd Wellness Inc. has engaged MNP LLP to audit its financial statements ahead of a potential IPO, following the appointment of a New York investment bank to advise on capital raising efforts. This move is part of a broader strategy led by CEO John Duffy, who brings extensive beverage industry experience to the company.
Quantum BioPharma is also settling debts with two vendors, issuing Class B Shares as payment, a transaction expected to finalize in early June 2025.
The company, through its subsidiary Lucid Psycheceuticals Inc., continues to develop its lead compound, Lucid-MS, aimed at treating neurodegenerative disorders. Quantum BioPharma holds a 20.11% stake in Unbuzzd Wellness Inc. as of March 31, 2025, and retains the rights to develop pharmaceutical versions of its alcohol misuse treatment products. While the company reported negative EBITDA of $16.78 million in the last twelve months, investors should note its next earnings report is scheduled for August 13, 2025.
This information is based on a press release statement from Quantum BioPharma.
In other recent news, Quantum BioPharma Ltd. has engaged MNP LLP to audit its financial statements in preparation for a potential initial public offering (IPO). This decision follows the resignation of its previous auditor, Stern & Lovrics LLP. Additionally, Unbuzzd Wellness Inc., a subsidiary of Quantum BioPharma, will undergo PCAOB audits by MNP as it explores an IPO. Quantum BioPharma has also selected BitGo Trust Company to manage and store its cryptocurrency holdings, including Bitcoin and DOGE coin, to ensure secure custodianship of its digital assets. In another development, the company has entered into an agreement to prepare an Investigational New Drug (IND) application for its multiple sclerosis treatment, Lucid-21-302, moving closer to a Phase 2 clinical trial. Quantum BioPharma has further strengthened its cryptocurrency portfolio by purchasing an additional $1 million in digital currencies, bringing its total investment to $4.5 million. The company has also appointed Kevin Malone as an advisor to its Board of Directors, enhancing its expertise in financial matters and market dynamics. These developments reflect Quantum BioPharma’s strategic initiatives in financial audits, digital assets management, drug development, and advisory expertise.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.